Medical treatment of vertigo

Year 2017, , 23 - 27, 16.03.2017

Serkan Tursun Gökçe Şimşek , Nuray Bayar Muluk

https://doi.org/10.18663/tjcl.298255

Abstract

Vertigo
(dizziness), constitutes a common group of diseases not only in the practice of
otolaryngology, also in the practice of family physicians. There are various
diseases in the etiology of this pathology and definitive diagnosis is not
always possible. The primary objective in the treatment should be reduction of
symptoms in the patients with acute attacks of vertigo. In this section,
medical treatment of vertigo will be described with mentioning of the current
medications and their therapeutic doses available dosage in our country.

Keywords

Vertigo, medical therapy

Vertigonun medikal tedavisi

Abstract

Vertigo
(baş dönmesi), sadece kulak burun boğaz değil, aile hekimliği pratiğinde de sık
rastlanan bir hastalık grubunu oluşturmaktadır. Etyolojisinde çok çeşitli
hastalıkların bulunduğu bu patolojinin kesin tanısı her zaman mümkün
olamamaktadır. Tedavide öncelikli amaç, akut vertigo atağı ile gelen hastanın semptomlarının
azaltılması olmalıdır. Vertigonun medikal tedavisinin anlatılacağı bu bölümde
ülkemizdeki mevcut ilaçlar ve tedavi dozlarından da bahsedilecektir. 

Keywords

Vertigo, medikal tedavi

References

• Ciuman RR. Inner ear symptoms and disease: Pathophysiological understanding and therapeutic options. Med Sci Monit 2013; 19: 1195-210.
• Huh YE, Kim JS. Bedside evaluation of dizzy patients. J Clin Neurol 2013; 9: 203-13.
• Zanni GR, Wick JY. Vertigo: few new spins on a common problem. Consult Pharm 2006; 21: 680-96.
• Sajjadi H, Paparella MM. Meniere's disease. Lancet 2008; 372: 406-14.
• Vademecum 2013 modern ilaç rehberi, 35.baskı, Nobel kitabevi.
• Zajonc TP, Roland PS. Vertigo and motion sickness. Part II: Pharmacologic treatment. Ear Nose Throat J 2006; 85: 25-35.
• Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005; 27: 655-65.
• Lin E, Aligene K. Pharmacology of balance and dizziness. NeuroRehabilitation 2013; 32: 529-42.
• Huppert D, Strupp M, Mückter H, Brandt T. Which medication do I need to manage dizzy patients? Acta Otolaryngol 2011; 131: 228-41.
• Venail F, Biboulet R, Mondain M, Uziel A. A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study. Eur Ann Otorhinolaryngol Head Neck Dis 2012; 129: 65-8.
• Della Pepa C, Guidetti G, Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngol Ital 2006; 26: 208-15.
• Nauta JJ. Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo. Eur Arch Otorhinolaryngol 201; 217: 887-97.
• Mukhopadhyay S, Niyogi M, Ray R, Mukhopadhyay BS, Dutta M, Mukherjee M. Betahistine as an add-on: The magic bullet for postoperative nausea, vomiting and dizziness after middle ear surgery? J Anaesthesiol Clin Pharmacol 2013; 29: 205-10.
• James AL, Thorp MA. Menière's disease. Clin Evid (Online). 2007 Mar 1; 2007. pii: 0505.
• Orhan I, Aydın S, Altın G, Yılmaz F. An efficacy comparison of betahistin, trimetazidine and ginkgo biloba extract in patients with tinnitus. Kulak Burun Bogaz Ihtis Derg 2013; 23: 143-7.
• Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. Eur Arch Otorhinolaryngol 2014; 271: 2931-6.
• Cesarani A, Meloni F, Alpini D, Barozzi S, Verderio L, Boscani PF. Ginkgo biloba (EGb 761) in the treatment of equilibrium disorders. Adv Ther 1998; 15: 291-304.
• Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000; 81: 668-78.
• Maclennan K, Smith PF, Darlington CL. Ginkgolide B accelerates vestibular compensation of spontaneous ocular nystagmus in guinea pig following unilateral labyrinthectomy. Exp Neurol 1995; 131: 273-8.
• Sekitani T, Imate Y, Noguchi T, Inokuma T. Vestibular neuronitis: epidemiological survey by questionnaire in Japan. Acta Otolaryngol Suppl 1993; 503: 9-12.
• Silvoniemi P. Vestibular neuronitis. An otoneurological evaluation. Acta Otolaryngol Suppl 1988; 453: 1-72.
• Hirata Y, Gyo K, Yanagihara N. Herpetic vestibular neuritis: an experimental study. Acta Otolaryngol Suppl 1995; 519: 93-6.
• Ariyasu L, Byl FM, Sprague MS, Adour KK. The beneficial effect of methylprednisolone in acute vestibular vertigo. Arch Otolaryngol Head Neck Surg 1990; 116: 700-3.
• Dutia MB. Mechanisms of vestibular compensation: recent advances. Curr Opin Otolaryngol Head Neck Surg 2010; 18: 420-4.
• Akagi H, Yuen K, Maeda Y, et al. Ménière’s disease in childhood. Int J Pediatr Otorhinolaryngol 2001; 61: 259–64.
• Russell G, Abu-Arafeh I. Paroxysmal vertigo in children an epidemiological study, Int J Pediatr Otorhinolaryngol 1999; 1:105-7.
• Filipo R, Barbara M, Juvenile Me´nie`re’s disease, J Laryngol Otol 1985; 99: 193-6.
• Parving A, Me´nie`re’s disease in childhood, J Laryngol Otol 1976; 90: 817-21.
• Nedzelski JM, Bryce GE, Pfleiderer AG. Treatment of Me´nie`re’s disease with topical gentamicin: A preliminary report, J Otolaryngol 1992; 21: 95-101.